HeyJaredChelsie Derman
- Indexed articles, last 90 days
- 4
- Latest publication
- Oct 1, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 28, 2026
Latest articles
Viaskin Peanut Patch BLA Submitted for Peanut Allergy in Children Aged 4-7 Years | HCPLive (opens the original)
Read excerpt
The Viaskin Peanut Patch is an investigational epicutaneous immunotherapy from DBV Technologies delivering 250 µg of peanut protein through intact skin to desensitize children with peanut allergy. It is not FDA approved. The BLA seeks approval for children aged 4 through 7 years with peanut allergy. DBV is separately studying the patch in toddlers aged 1 through 3 years. At 12 months, 46.6% of children treated with the patch met responder criteria vs 14.8% with placebo, with a 95% CI lower bound
Phase 3 PARADIGM: HLP003 (Psilocibin-d10) for Adjunctive MDD Use | HCPLive (opens the original)
Read excerpt
HLP003, formerly CYB003, is an investigational oral deuterated psilocin analog in phase 3 development as an adjunctive treatment for MDD. It holds FDA Breakthrough Therapy Designation. APPROACH and EMBRACE compare 2 doses of HLP003 given 21 days apart with placebo in adults on a stable antidepressant, with MADRS change at Day 42 as the primary endpoint. EXTEND evaluates durability and re-treatment through 43 weeks. Helus Pharma expects APPROACH topline data in the fourth quarter of 2026, with EM
Hereditary Angioedema Triggers, Prodromes Mapped in US HAEA Registry | HCPLive (opens the original)
Read excerpt
Key TakeawaysStress was the most common attack trigger in both the HAE-C1INH (91.5%) and ANM-nl-C1INH (81.25%) cohorts of the US HAEA Scientific Registry.Hormonal triggers in HAE-C1INH and menses in ANM-nl-C1INH were the triggers most likely to always be followed by an attack.A sense or hunch of an impending attack was the most reliable prodrome in HAE-C1INH (47.4%), versus tightness or prickling in ANM-nl-C1INH (62.2%).
Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome | HCPLive (opens the original)
Read excerpt
AGS is a tick bite-associated IgE-mediated allergy to galactose-alpha-1,3-galactose, an oligosaccharide present in nonprimate mammalian meat and tissue-derived products, including cetuximab. The antibodies bind alpha-gal epitopes on allergens and physically block patient IgE from engaging them, preventing the FcεRI cross-linking on basophils and mast cells that drives allergic reactions. Of 42 anti-alpha-gal mAbs screened, 13 bound major AGS allergens and 2 blocked patient serum IgE binding. AG0
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.